Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Quanscient | $5,667,883 | (Nov 5, 2024)
Trait Biosciences Inc.
United States
- Santa Fe, New Mexico
- 13/10/2023
- Unknown
- Undisclosed Amount
Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products.
With a world-class team of scientists collaborating in a state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science.
Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp.
Our solutions have broad applications across industries. Visit www.traitbio.com to learn more.
- Industry Biotechnology Research
- Website https://traitbio.com/
- LinkedIn https://www.linkedin.com/company/traitbio/about/
Related People
Edward CheungCo Founder
Hong Kong -
ND
Edward is a co-founder of Trait Biosciences and Pebble Labs.
Trait Biosciences, is a global leader in cannabinoid research, focused on developing technologies that enables the production of safe, high-quality, low cost, predictable, and efficacious cannabidiol products including truly water-soluble cannabinoids which can be used in food & beverage nutraceuticals and pharmaceutical drugs.
Pebble Labs is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security.
Edward has over 20 years experience in Equity and Derivatives Sales Trading at investment banks in London, Singapore, Seoul and Hong Kong. During his career he has held positions at JP Morgan, Lehman Brothers, Credit Suisse, RBS and most recently as Asia-Pacific head of listed derivatives trading for the Asia markets at State Street Bank & Trust. Since moving to Asia in 1998 he has been in sales & trading for Asia Pacific equities, derivatives, exotic products and IPOs to institutions, asset managers, hedge funds, and sovereign wealth funds.
Miros | $6,535,520 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Inquis Medical, Inc. | $40,000,000 | (Nov 5, 2024)
CrossBridge Bio | $10,000,000 | (Nov 5, 2024)